Post spike syndrome (PSS): Simple solution leading to resolving results, five cases report.
- 2025
- IDCases 41
- PubMed: 40671933
- DOI: 10.1016/j.idcr.2025.e02278
Study Design
- Type
- Case Report
- Population
- five patients diagnosed with interstitial granulomatous dermatitis, polymyalgia rheumatica, peripheral polyneuropathy, drug-refractory epilepsy, and trigeminal neuralgia
- Methods
- This case series includes five patients... A simple therapeutic approach was applied to five patients... A broad intervention including a focus on restoring the microbiome, in particular Bifidobacterium associated with ivermectin and nattokinase was used as a therapeutic strategy. This is an observational and descriptive study, with data collected retrospectively from medical records at a private clinic in São Paulo, Brazil.
Methods
This case series includes five patients diagnosed with interstitial granulomatous dermatitis, polymyalgia rheumatica, peripheral polyneuropathy, drug-refractory epilepsy, and trigeminal neuralgia. A common pathophysiological mechanism-vasculitis triggered by both SARS-CoV-2 and mRNA-based therapies-was hypothesised. The patients exhibited a satisfactory response to the proposed therapeutic strategy. This is an observational and descriptive study, with data collected retrospectively from medical records at a private clinic in São Paulo, Brazil.Conclusion
It is crucial to raise awareness within the medical community About SPIKEOPATHY, particularly in cases of classic pathologies that do not respond to conventional treatments. We believe PSS is currently underestimated. A broad intervention including a focus on restoring the microbiome, in particular Bifidobacterium associated with ivermectin and nattokinase was used as a therapeutic strategy. In other studies, Bifidobacterium has already been shown to significantly reduce harmful bactéria in post-COVID patients. Further studies are needed to confirm these findings and expand our understanding of PSS management.Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|---|---|---|---|---|
| Bifidobacterium bifidum Bb-02 | — | Improved Symptoms | Beneficial | Moderate | View sourceA broad intervention including a focus on restoring the microbiome, in particular Bifidobacterium associated with ivermectin and nattokinase was used as a therapeutic strategy... The patients exhibited a satisfactory response to the proposed therapeutic strategy. |
| Bifidobacterium bifidum BB-06 | — | Improved Symptoms in Post-Spike Syndrome | Beneficial | Moderate | View sourceA simple therapeutic approach was applied to five patients, resulting in notable symptom improvement... The patients exhibited a satisfactory response to the proposed therapeutic strategy... a focus on restoring the microbiome, in particular Bifidobacterium associated with ivermectin and nattokinase was used as a therapeutic strategy. |
| Bifidobacterium lactis Bb-02 | — | Improved Symptoms | Beneficial | Moderate | View sourceA broad intervention including a focus on restoring the microbiome, in particular Bifidobacterium associated with ivermectin and nattokinase was used as a therapeutic strategy... The patients exhibited a satisfactory response to the proposed therapeutic strategy. |
| Bifidobacterium lactis BI-04 | — | Improved Gut Microbiome Composition | Beneficial | Small | View sourceA broad intervention including a focus on restoring the microbiome, in particular Bifidobacterium... was used as a therapeutic strategy. |
| Bifidobacterium lactis BI-04 | — | Improved Multisystem Symptoms | Beneficial | Moderate | View sourceThe patients exhibited a satisfactory response to the proposed therapeutic strategy. |
| Bifidobacterium lactis Bi-07 | — | Improved Symptoms | Beneficial | Moderate | View sourceA broad intervention including a focus on restoring the microbiome, in particular Bifidobacterium associated with ivermectin and nattokinase was used as a therapeutic strategy... The patients exhibited a satisfactory response to the proposed therapeutic strategy. |